General Information


DRAVP ID  DRAVPe00103

Peptide Name   EBR28[Y9A]

Sequence  YQLLIRMIAKNI

Sequence Length  12

UniProt ID  No entry found

Source  Synthetic construct



Activity Information


Target Organism  HIV

Assay  Disintegration assay

Activity 

  • [Ref.12054767]HIV-1:Inhibition of 3′-end processing catalyzed by integrase(IC50=40 µM);inhibition of HIV-1 infection in HeLa CD4-β-Gal cells(IC50~100 μM).

Hemolytic Activity  No hemolysis information or data found in the reference(s) presented in this entry

Cytotoxicity 

  • [Ref.12054767]P4 cells: Cell viability estimated by the MTT assay was decreased by about 5% at peptide concentrations higher than 100 μM.

Binding Target  Integrase

Mechanism  Binding of both viral DNA and host chromosomal DNA are critical steps in IN-catalyzed reactions. The peptide interacted with the catalytic domain of IN interfering with the binding of the DNA substrate and inhibit the replication of virus.



Structure Information


PDB ID  None

Predicted Structure Download  DRAVPe00103

Linear/Cyclic  Linear

N-terminal Modification  Free

C-terminal Modification  Free

Other Modification  None

Stereochemistry  L



Physicochemical Information


Formula  C68H118N18O16S

Absent amino acids  CDEFGHPSTVW

Common amino acids  I

Mass  1475.86

Pl  9.99

Basic residues  2

Acidic residues  0

Hydrophobic residues  6

Net charge  2

Boman Index  -403

Hydrophobicity  67.5

Aliphatic Index  170.83

Half Life 

  •     Mammalian:2.8 hour
  •     Yeast:10 min
  •     E.coli:2 min

Extinction Coefficient cystines  1490

Absorbance 280nm  135.45

Polar residues  2



Literature Information


Literature 1

Title   A novel short peptide is a specific inhibitor of the human immunodeficiency virus type 1 integrase.

Pubmed ID   12054767

Reference   J Mol Biol. 2002 Apr 19;318(1):45-58.

Author   de Soultrait VR, Caumont A, Parissi V, Morellet N, Ventura M, Lenoir C, Litvak S, Fournier M, Roques B. 

DOI   10.1016/S0022-2836(02)00033-5